Amgen Inc. (NASDAQ:AMGN) Shares Sold by Fiduciary Trust Co

Fiduciary Trust Co decreased its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 2.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 51,890 shares of the medical research company's stock after selling 1,405 shares during the quarter. Fiduciary Trust Co's holdings in Amgen were worth $13,525,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Beck Mack & Oliver LLC grew its holdings in Amgen by 0.7% during the 4th quarter. Beck Mack & Oliver LLC now owns 4,623 shares of the medical research company's stock valued at $1,205,000 after buying an additional 34 shares in the last quarter. Blossom Wealth Management grew its holdings in shares of Amgen by 3.5% during the fourth quarter. Blossom Wealth Management now owns 1,090 shares of the medical research company's stock worth $284,000 after purchasing an additional 37 shares in the last quarter. Zullo Investment Group Inc. grew its holdings in shares of Amgen by 2.8% during the fourth quarter. Zullo Investment Group Inc. now owns 1,364 shares of the medical research company's stock worth $356,000 after purchasing an additional 37 shares in the last quarter. Trillium Asset Management LLC lifted its position in Amgen by 4.2% in the 4th quarter. Trillium Asset Management LLC now owns 911 shares of the medical research company's stock worth $237,000 after buying an additional 37 shares during the last quarter. Finally, Evermay Wealth Management LLC lifted its position in Amgen by 1.5% in the 4th quarter. Evermay Wealth Management LLC now owns 2,650 shares of the medical research company's stock worth $691,000 after buying an additional 38 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.

Insider Transactions at Amgen

In other news, EVP Murdo Gordon sold 8,771 shares of the firm's stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the completion of the sale, the executive vice president now owns 44,186 shares in the company, valued at $13,025,590.94. This trade represents a 16.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP David M. Reese sold 25,225 shares of the firm's stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the sale, the executive vice president now owns 36,922 shares of the company's stock, valued at $11,240,533.68. This represents a 40.59% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 42,707 shares of company stock valued at $12,819,342. Corporate insiders own 0.69% of the company's stock.

Amgen Stock Performance

Shares of AMGN stock traded down $6.19 on Friday, hitting $265.86. The company had a trading volume of 3,326,938 shares, compared to its average volume of 2,766,734. The firm has a market cap of $142.94 billion, a P/E ratio of 35.21, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. The company has a 50-day moving average price of $296.08 and a 200-day moving average price of $289.50. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, topping analysts' consensus estimates of $4.18 by $0.72. The company had revenue of $8.15 billion during the quarter, compared to analysts' expectations of $8.05 billion. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Amgen's quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.96 EPS. As a group, equities research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be given a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.58%. The ex-dividend date is Friday, May 16th. Amgen's dividend payout ratio (DPR) is 86.86%.

Analyst Upgrades and Downgrades

Several analysts have weighed in on AMGN shares. Morgan Stanley reiterated an "equal weight" rating on shares of Amgen in a research report on Friday, May 2nd. Citigroup reiterated a "neutral" rating on shares of Amgen in a research report on Wednesday, February 5th. Cantor Fitzgerald started coverage on Amgen in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $305.00 price objective for the company. Royal Bank of Canada lowered their price objective on Amgen from $324.00 to $320.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Finally, UBS Group reiterated a "neutral" rating and issued a $315.00 price objective (down previously from $319.00) on shares of Amgen in a research report on Friday, May 2nd. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $310.23.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.